Adverse events (preferred term) Omalizumab powder for solution (n= 81)n (%) Omalizumab solution (n= 74)n (%) Total (n= 155) n (%)
Headache 21 (25.9) 16 (21.6) 37 (23.9)
Sinus congestion 6 (7.4) 7 (9.5) 13 (8.4)
Rhinorrhoea 4 (4.9) 7 (9.5) 11 (7.1)
Pharyngolaryngeal pain 8 (9.9) 3 (4.1) 11 (7.1)
Sneezing 5 (6.2) 3 (4.1) 8 (5.2)
Nausea 5 (6.2) 3 (4.1) 8 (5.2)
Nasal congestion 3 (3.7) 4 (5.4) 7 (4.5)
Vomiting 3 (3.7) 2 (2.7) 5 (3.2)
Arthralgia 4 (4.9) 1 (1.4) 5 (3.2)
Nasopharyngitis 1 (1.2) 4 (5.4) 5 (3.2)
Table 5: Most commonly reported adverse events (>4 subjects in the overall study population).
Goto home»